Aurinia Pharmaceuticals (AUPH) Operating Leases (2019 - 2025)
Historic Operating Leases for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Q3 2025 value amounting to $6.2 million.
- Aurinia Pharmaceuticals' Operating Leases fell 1137.9% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year decrease of 1137.9%. This contributed to the annual value of $5.7 million for FY2024, which is 1205.21% down from last year.
- Aurinia Pharmaceuticals' Operating Leases amounted to $6.2 million in Q3 2025, which was down 1137.9% from $6.4 million recorded in Q2 2025.
- Aurinia Pharmaceuticals' Operating Leases' 5-year high stood at $8.9 million during Q2 2021, with a 5-year trough of $5.7 million in Q4 2024.
- Over the past 5 years, Aurinia Pharmaceuticals' median Operating Leases value was $7.7 million (recorded in 2021), while the average stood at $7.5 million.
- In the last 5 years, Aurinia Pharmaceuticals' Operating Leases surged by 5178.6% in 2021 and then plummeted by 1205.21% in 2024.
- Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Operating Leases stood at $7.7 million in 2021, then dropped by 6.88% to $7.2 million in 2022, then dropped by 8.7% to $6.5 million in 2023, then dropped by 12.05% to $5.7 million in 2024, then rose by 7.54% to $6.2 million in 2025.
- Its Operating Leases was $6.2 million in Q3 2025, compared to $6.4 million in Q2 2025 and $6.6 million in Q1 2025.